Eruptive Xanthoma During Antiretroviral Therapy

Abstract

We present a case of eruptive xanthoma in a man living with HIV after changing antiretroviral therapy. People living with HIV are at increased risk of dyslipidemia due to the infection itself and the use of antiretroviral medications. Prompt recognition of eruptive xanthomas may allow for timely diagnosis of metabolic disorders and dyslipidemia in patients being treated for HIV infection.  J Microbiol Infect Dis 2019; 9(1): 43-45.

Keywords

• Eruptive xanthoma,hypertriglyceridemia,metabolic syndrome,HIV,dolutegravir

References

1. 1. Kashif M, Kumar H, Khaja M. An Unusual Presentation of Eruptive Xanthoma: A Case Report and Literature Review. Ed. Sergio Gonzalez Bombardiere. Medicine 2016; 95(37): e4866. 2. da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol 2015; 4(2): 56-77. 3. Campbell SM, Crowe SM, Mak J. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 2002; 16(17):2253-2261. 4. Tivicay Dolutegravir (as dolutegravir sodium). Laval, Quebec, Canada: ViiV Healthcare ULC; February 2017. 5. Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks. Clin Drug Investig 2015; 35(3): 211-219.